Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review

Show other versions (1)

Background Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy and safety....

Full description

Bibliographic Details
Published in:	Pulmonology
Main Authors:	A. Cortegiani, M. Ippolito, M. Greco, V. Granone, A. Protti, C. Gregoretti, A. Giarratano, S. Einav, M. Cecconi
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2021-01-01
Subjects:	COVID-19 Tocilizumab SARS-CoV-2 Pneumonia Coronavirus
Online Access:	https://www.tandfonline.com/doi/10.1016/j.pulmoe.2020.07.003

Similar Items

Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review
by: A. Cortegiani, et al.
Published: (2021-01-01)

Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study
by: Tariq Kewan, et al.
Published: (2020-07-01)

The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial
by: Farzaneh Dastan, et al.
Published: (2023-10-01)

Pneumococcal meningitis in a patient with severe COVID-19 on dexamethasone and tocilizumab: A case report
by: Yoshiaki Murayama, et al.
Published: (2023-01-01)

Tocilizumab in COVID-19: A Double-Edged Sword?
by: Bartosz Kudliński, et al.
Published: (2024-12-01)

First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia
by: Omar Valenzuela, et al.
Published: (2020-11-01)

Tocilizumab or glucocorticoids treatment for patients with SARS-CoV-2 pneumonia: An observational study
by: Giovanni Dolci, et al.
Published: (2022-01-01)

Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study
by: Matilde Sánchez-Conde, et al.
Published: (2022-10-01)

The association between tocilizumab and the secondary bloodstream infection maybe nonsignificant in hospitalized patients with SARS-CoV-2 infection: A cohort study
by: De-En Lu, et al.
Published: (2024-02-01)

Tocilizumab is associated with reduced delirium and coma in critically ill patients with COVID-19
by: Tuqa Alkhateeb, et al.
Published: (2024-05-01)

Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes
by: Abeer Al-Baadani, et al.
Published: (2021-08-01)

A retrospective evaluation of COVID-19 patients treated with Tocilizumab: who should be treated?
by: Semiha Çelik Ekinci, et al.
Published: (2021-12-01)

Prognostic immune markers identifying patients with severe COVID-19 who respond to tocilizumab
by: Sara De Biasi, et al.
Published: (2023-05-01)

Evaluating the efficacy of different doses of tocilizumab in treating critically ill COVID–19 patients: a single–center retrospective cohort study
by: Jie Gao, et al.
Published: (2025-07-01)

Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study
by: Wael Hafez, et al.
Published: (2022-02-01)

Tocilizumab as a Treatment for ‘Cytokine Storm Syndrome’ in COVID-19: A Case Report
by: Ari Fahrial Syam, et al.
Published: (2021-07-01)

Baricitinib vs tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: a prospective, investigational, real-world study
by: Botond Lakatos, et al.
Published: (2022-12-01)

A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages
by: Maaike C. Swets, et al.
Published: (2023-04-01)

Factors Influencing Disease Stability and Response to Tocilizumab Therapy in Severe COVID-19: A Retrospective Cohort Study
by: Wael Hafez, et al.
Published: (2022-08-01)

How to follow-up a patient who received tocilizumab in severe COVID-19: a case report
by: Regina B. Podlasin, et al.
Published: (2020-08-01)

Tocilizumab versus anakinra in COVID-19: results from propensity score matching
by: Robin Arcani, et al.
Published: (2023-05-01)

Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors’ reply
by: A. Cortegiani, et al.
Published: (2021-01-01)

Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors’ reply
by: A. Cortegiani, et al.
Published: (2021-01-01)

Clinical Outcomes among Hospitalized COVID-19 Patients Who Received Baricitinib or Tocilizumab in Addition to Standard of Care
by: Cucnhat P. Walker, et al.
Published: (2024-05-01)

Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation
by: Francesco Menzella, et al.
Published: (2020-09-01)

Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia
by: Daria Fomina, et al.
Published: (2020-10-01)

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
by: Francesco Perrone, et al.
Published: (2020-10-01)

Incidence of secondary bacterial infections following utilization of tocilizumab for the treatment of COVID-19 – A matched retrospective cohort study
by: Joanna L Moore, et al.
Published: (2021-01-01)

Influence of anti-Spike protein antibody levels on tocilizumab efficacy in hospitalized patients with severe COVID-19 pneumonia: a post-hoc analysis of the COVACTA trial
by: José Aguareles, et al.
Published: (2025-05-01)

Why tocilizumab could be an effective treatment for severe COVID-19?
by: Binqing Fu, et al.
Published: (2020-04-01)

The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review
by: Avi Gurion Kaye, et al.
Published: (2020-11-01)

Evaluation of the Efficacy of Tocilizumab in Cytokine Release Syndrome in Patients with COVID-19 (SARS-CoV-2) Pneumonia Followed in the Intensive Care Unit
by: Serpil Şehirlioğlu, et al.
Published: (2025-09-01)

A retrospective analysis of moderate and severe COVID-19 pneumonia with special reference to the use of Adjuvant Tocilizumab
by: Pratik Raval, et al.
Published: (2022-01-01)

Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 Treated with Tocilizumab
by: Carmen Niño-Taravilla, et al.
Published: (2020-12-01)

Tratamiento con Tocilizumab en COVID-19 crítico: Reporte de un centro hospitalario [Breve]
by: Miguel Hueda Zavaleta, et al.
Published: (2021-08-01)

A case series of coinfection with SARS-CoV-2 and influenza virus in Louisiana
by: Jennifer L. Miatech, et al.
Published: (2020-01-01)

A Case Series of Severe Hospitalized COVID-19 Patients Treated with Tocilizumab and Glucocorticoids: A Report from Saudi Arabian Hospital
by: Salma AlBahrani, et al.
Published: (2021-01-01)

Tocilizumab prescribing criteria for COVID-19 patients
by: Ayman M. Al-Qaaneh, et al.
Published: (2021-04-01)

Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients
by: Bogna Grygiel-Górniak, et al.
Published: (2021-08-01)

Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19
by: V. T. Ivashkin, et al.
Published: (2023-12-01)